Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis

Clinical Cancer Research

Volumn 15, Issue 16, 2009, Pages 5082-5091

  Patiño García, Ana ^a   Zalacain, Marta ^a   Folio, Cecilia ^a,c   Zandueta, Carolina ^c   Sierrasesúmaga, Luis ^a   San Julián, Mikel ^b   Toledo, Gemma ^a,e   De Las Rivas, Javier ^d   Lecanda, Fernando ^c  

^a Universidad Pública de Navarra   (Spain)

^b University Hospital   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d Centro de Investigacion del Cancer   (Spain)

^e MD ANDERSON CANCER CENTER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; OSTEOPROTEGERIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EBF2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL ISOLATION; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LENTIVIRINAE; MALE; MICROARRAY ANALYSIS; ONCOGENE; OSTEOBLAST; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; TRANSCRIPTION INITIATION; TRANSCRIPTOMICS; VIRAL GENE DELIVERY SYSTEM;

ADOLESCENT; ADULT; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BONE NEOPLASMS; CELLS, CULTURED; CHILD; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATCHED-PAIR ANALYSIS; OSTEOPROTEGERIN; OSTEOSARCOMA; SURVIVAL ANALYSIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; YOUNG ADULT;

EID: 69349092973     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0300     Document Type: Article

References (40)

1. Fletcher CDM, Unni KK, Mertens F, Organización Mundial de la Salud, International Academy of Pathology, International Agency for Research on Cancer. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002.
2. GorlickR, Anderson P, Andrulis I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 2003;9:5442-5453 (Pubitemid 37499462)
3. Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma. DNA Cell Biol 2007;26:1-18.
4. ClarkJC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008;134: 281-297 (Pubitemid 351170066)
5. Bridge JA, Nelson M, McComb E, et al. Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet Cytogenet 1997;95:74-87. (Pubitemid 27188450)
6. Atiye J, Wolf M, Kaur S, et al. Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer 2005; 42:158-163 (Pubitemid 40094099)
7. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 2003;145:1-30. (Pubitemid 36926284)
8. Mackall CL, Meltzer PS, Helman LJ. Focus on sarcomas. Cancer Cell 2002;2:175-178
9. Lecanda F, Avioli LV, Cheng SL. Regulation of bone matrix protein expression and induction of differentiation of human osteoblasts and human bone marrow stromal cel l s by bone morphogenetic protein-2. J Cell Biochem 1997;67:386-396 (Pubitemid 27509474)
10. Leonard P, Sharp T, Henderson S, et al. Gene expression array profile of human osteosarcoma. Br J Cancer 2003;89:2284-2288 (Pubitemid 38168012)
11. Wolf M, El-Rifai W, Tarkkanen M, et al. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genet Cytogenet 2000;123:128-132 (Pubitemid 32012494)
12. Nielsen TO. Microarray analysis of sarcomas. Adv Anat Pathol 2006;13:166-173
13. Baird K, Davis S, Antonescu CR, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005;65: 9226-9235 (Pubitemid 41507988)
14. Kieslinger M, Folberth S, Dobreva G, et al. EBF2 regulates osteoblast-dependent differentiation of osteoclasts. Dev Cell 2005;9:757-767 (Pubitemid 41724104)
15. Lecanda F, Warlow PM, Sheikh S, Furlan F, Steinberg TH, Civitelli R. Connexin43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J Cell Biol 2000;151:931-944 (Pubitemid 30945468)
16. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-193 (Pubitemid 36181903)
17. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
18. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-264
19. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-5121 (Pubitemid 32397092)
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B 1995;57:289-300.
21. Murtagh F. Multidimensional clustering algorithms: COMPSTAT Lectures 4. Wuerzburg: Physica-Verlag; 1985.
22. Vicent S, Luis-Ravelo D, Anton I, et al. A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res 2008;68:2275-2285
23. van Maanen JM, Retel J, de Vries J, Pinedo HM. Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst 1988;80: 1526-1533 (Pubitemid 19009648)
24. Kovacic N, Lukic IK, Grcevic D, Katavic V, Croucher P, Marusic A. The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis. J Immunol 2007;178:3379-3389 (Pubitemid 46417602)
25. Hoang BH, Kubo T, Healey JH, et al. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004; 109:106-111 (Pubitemid 38160669)
26. Hoang BH, Kubo T, Healey JH, et al. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-β-catenin pathway. Cancer Res 2004;64:2734-2739 (Pubitemid 38500609)
27. Secchiero P, Corallini F, Rimondi E, et al. Activation of the p53 pathway down-regulates the osteoprotegerin (OPG) expression and release by vascular endothelial cells. Blood 2008;111: 1287-1294 (Pubitemid 351213412)
28. Glass DA II, BialekP, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005;8: 751-764 (Pubitemid 40585297)
29. Evdokiou A, Bouralexis S, Atkins GJ, et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002;99:491-504. (Pubitemid 34461601)
30. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002; 62:1619-1623 (Pubitemid 34408480)
31. Holen I, Cross SS, Neville-Webbe HL, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo-a role in tumour cell survival? Breast Cancer Res Treat 2005;92:207-215
32. Fisher JL, Thomas-Mudge RJ, Elliott J, et al. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 2006;66: 3620-3628
33. Lamoureux F, Richard P, Wittrant Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 2007;67:7308-7318 (Pubitemid 47206560)
34. Sinicrope FA, Penington RC, Tang XM. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin Cancer Res 2004;10:8284-8292
35. Sun SY, Yue P, Zhou JY, et al. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun 2001;280:788-797 (Pubitemid 32924499)
36. Ricci MS, Kim SH, Ogi K, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007;12:66-80. (Pubitemid 47001783)
37. Lamoureux F, Picarda G, Garrigue-Antar L, et al. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res 2009;69:526-536
38. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003;63:912-916
39. Selvarajah S, Yoshimoto M, Ludkovski O, et al. Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenet Genome Res 2008;122:5-15.
40. Engin F, Yao Z, Yang T, et al. Dimorphic effects of Notch signaling in bone homeostasis. Nat Med 2008;14:299-305. (Pubitemid 351347909)